Professor Chng Wee Joo

Director, National University Cancer Institute, Singapore (NCIS)

Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS) 

Leader, Haematologic Malignancy Tumour Group, National University Cancer Institute, Singapore (NCIS) 

Professor, Yong Loo Lin School of Medicine, National University of Singapore 

Deputy Director, Cancer Science Institute of Singapore, National University of Singapore

 

Prof Chng is the Director of the National University Cancer Institute, Singapore (NCIS).


Prof Chng obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. Fellowship training in haematology was completed in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics. His current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.

 

Education and Fellowships

MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS

 

Specialty Interests

  • Multiple Myeloma
  • Lymphoma

Awards and Honours

  • 2017 - NUS YLL SOM Outstanding Researcher of the Year Award
  • 2017 - NMRC Senior Translational (STaR) Research Award
  • 2016 - 26th Seah Cheng Siang Memorial Lecture
  • 2016 - NMEA National Outstanding Clinician-Scientist Award
  • 2012 - NMRC Clinician Scientist (Senior) Award
  • 2011 - Chua Hua Toh Memorial Gold Medal (Best Graduate Thesis in Life Science)
  • 2011 - NUS Young Research Award
  • 2010 - YLL SOM Faculty Outstanding Researcher Award (Young Researcher Category)
  • 2009 - JCI The Outstanding Young Persons Award
  • 2008 - NMRC Clinician Scientist Award
  • 2007 - Celgene Future Leaders in Haematology Award
  • 2007 - SMJ Best Reviewer Award 2006
  • 2006 - 2007 Multiple Myeloma Research Foundation
  • 2006 - Singapore Medical Journal Best Research Paper 2005 (Second Prize)
  • 2004 - 2006 A*Star International Fellowship
  • 2004 - Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation
  • 2003 - Courage Star
  • 2002 - Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation

 

Professional Memberships

  • American Society of Haematology
  • American Association of Cancer Research
  • International Myeloma Working Group
  • Asian Myeloma Network
  • Singapore Society of Haematology

 

Selected Publications

  1. *WJ Chng, H Goldschmidt, MA Dimopoulos, P Moreau, D Joshua, A Palumbo, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosiñol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, HH Gillenwater, N Mohamed, S Feng, S Aggarwal, and R Hájek. Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis From the Phase 3 Study ENDEAVOR. Leukemia 2017; 31: 1368-74.

  2. Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, Bi C, Lee XT, Selvarajan V, Ng SB, Yang H, Yu Q, *Chng WJ. EZH2 phosphorylation by JAK3 mediates a switch to non-canonical function in natural killer/T-cell lymphoma. Blood 2016; 128: 948-58. [IF 11.8].

  3. Mahara S, Lee PL, Feng M, Tergaonkar V, *Chng WJ, Yu Q. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci U S A 2016: 113: E3735-44. [IF 9.4].

  4. Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia 2016; 30: 1071-8. 

  5. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27-38. [IF 26.5].

  6. PSY Chong, J Zhou, LL Cheong, SC Liu, J Qian, T Guo, SK Sze, Q Zeng, *WJ Chng. LEO1 is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myeloid Leukemia. Cancer Res 2014; 74: 3043-3053.

  7. Z Xie, C Bi, JY Chooi, ZL Chan, N Mustafa, and *WJ Chng. MMSET regulates transcription factors critical for survival of t(4;14) myeloma myeloma cells and its silence potentiates the effect of antimyeloma agents. Leukemia 2015; 29: 2347-54 [IF 12.1]

  8. PJ Teoh, TH Chung, C Sintosebastian, J Yan, SB Ng, R Fonseca, *WJ Chng. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 2014. 28: 2066-74. [IF – 12.1].

  9. WJ Chng, SA Van Wier, G Ahmann, et al. A validated FISH Trisomy Index Demonstrates the Hyperdiploid and non-hyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156-2161. [IF – 10.56]
  10. WJ Chng, G Ahmann, K Henderson, et al. Clinical implication of centrosome abnormalities in Plasma Cell Neoplasm. Blood 2006; 107: 3669-3675. [IF – 10.56]
  11. WJ Chng, S Kumar, S Van Wier, et al. Molecular dissection of hyperdiploid myeloma using gene expression profiling. Cancer Res 2007; 67: 2982-2989. [IF – 7.54]
  12. WJ Chng, E Braggio, R Valdez, G Mulligan, B Bryant, E Remstein, A Dogan, R Fonseca. The centrosome index is a powerful prognostic marker in multiple myeloma and identifies a cohort of patients that may benefit from aurora kinase inhibition. Blood 2008; 111: 1603-1609. [IF – 10.56]
  13. WJ Chng, TH Chung, S Van Wier, et al. Correlation between Array-Comparative Genomic Hybridization Defined Genomic Gains and Losses and Survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24: 833-842. [IF – 8.30]
  14. WJ Chng, GF Huang, TH Chung, et al. Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011 25 :1026-35 [IF – 8.30]
  15. SB Ng, V Selvarajan, G Huang, J Zhou, AL Feldman, M Law, YL Kwong, N Shimizu, Y Kagami, K Aozasa, M Salto-Tellez, WJ Chng. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011; 223: 496-510. 
  16. J Zhou, C Bi, LL Cheong, S Mahara, SC Liu, KG Tay, TL Koh, Q Yu, WJ Chng. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011; 118: 2830-9. [IF – 10.56]
  17. SB Ng, J Yan, G Huang, V Selvarajan, JL Tay, B Lin, C Bi, J Tan, YL Kwong, N Shimizu, K Aozasa, WJ Chng. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 201; 118: 4919-29. [IF – 10.56]
  18. J Yan, SB Ng, JL Tay, B Lin, TL Koh, J Tan, V Selvarajan, SC Liu, C Bi, S Wang, SN Choo, N Shimizu, G Huang, Q Yu and WJ Chng. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013; 121: 4512-4520
  19. WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, J San Miguel, P Sonneveld, S Umani, BDG Durie, H Avet-Loiseau on Behalf of the International Myeloma Working Group. IMWG Consensus on Risk Stratification in Multiple Myeloma. Leukemia 2014; 28: 269-77

 



Updated as of 19 June 2017